{"id":82223,"date":"2018-07-13T00:00:00","date_gmt":"2022-11-09T14:09:15","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/?post_type=eb_course&p=82223"},"modified":"2023-05-02T09:23:08","modified_gmt":"2023-05-02T13:23:08","slug":"the-evolving-landscape-of-hiv-treatment-qicpd-category-2","status":"publish","type":"eb_course","link":"https:\/\/www.mdbriefcase.com\/fr\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/","title":{"rendered":"The Evolving Landscape of HIV Treatment – QI&CPD – Category 2"},"content":{"rendered":"

Comorbidities usually occur earlier and more commonly in patients with chronic HIV infection. Management guidelines are therefore increasingly recommending regular screening for these conditions in patients with chronic HIV. Screening and treatment for common comorbidities are usually no different than for HIV-negative individuals, although special factors may need to be considered in the HIV-positive group.<\/p>","protected":false},"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-82223","eb_course","type-eb_course","status-publish","hentry"],"acf":[],"yoast_head":"\nThe Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Comorbidities usually occur earlier and more commonly in patients with chronic HIV infection. Management guidelines are therefore increasingly recommending regular screening for these conditions in patients with chronic HIV. Screening and treatment for common comorbidities are usually no different than for HIV-negative individuals, although special factors may need to be considered in the HIV-positive group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T13:23:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/\",\"name\":\"The Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\"},\"datePublished\":\"2022-11-09T14:09:15+00:00\",\"dateModified\":\"2023-05-02T13:23:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mdbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.mdbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Evolving Landscape of HIV Treatment – QI&CPD – Category 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mdbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/","og_locale":"fr_CA","og_type":"article","og_title":"The Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase","og_description":"Comorbidities usually occur earlier and more commonly in patients with chronic HIV infection. Management guidelines are therefore increasingly recommending regular screening for these conditions in patients with chronic HIV. Screening and treatment for common comorbidities are usually no different than for HIV-negative individuals, although special factors may need to be considered in the HIV-positive group.","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T13:23:08+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/","url":"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/","name":"The Evolving Landscape of HIV Treatment - QI&CPD - Category 2 - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"datePublished":"2022-11-09T14:09:15+00:00","dateModified":"2023-05-02T13:23:08+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/the-evolving-landscape-of-hiv-treatment-qicpd-category-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"The Evolving Landscape of HIV Treatment – QI&CPD – Category 2"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=82223"}],"version-history":[{"count":0,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/82223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=82223"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=82223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}